Journals / Turkish Neurosurgery / 2013 / Cilt: 23 - Sayı: 5

Preoperatif Embolizasyonla Kombine Mobil Omurga ve Sakrum Dev Hücreli Tümörü Nüksü Risk Faktörleri Analizi

Analysis of Risk Factors for Recurrence of giant Cel Tumor of the Sacrum and Mobile Spine Combined with Preoperative Embolization

Pages
645–652
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The choice of surgical treatment should be balanced between the complications and tumor recurrence.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: To investigate the factors related to the local recurrence-free survival time (LRFS) after surgical treatment of GCT of the sacrum and mobile spine combined with preoperative embolization.
📊
Key Findings & Data:MATERIAL and METHODS: We retrospectively reviewed 28 consecutive patients with GCT of the sacrum and mobile spine who underwent initial surgical excision combined with preoperative embolization between 1995 and 2011.
💡
Conclusion & Impact:The choice of surgical treatment should be balanced between the complications and tumor recurrence.
🔬Design:Review & Systematic Survey
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

AIM: To investigate the factors related to the local recurrence-free survival time (LRFS) after surgical treatment of GCT of the sacrum and mobile spine combined with preoperative embolization. MATERIAL and METHODS: We retrospectively reviewed 28 consecutive patients with GCT of the sacrum and mobile spine who underwent initial surgical excision combined with preoperative embolization between 1995 and 2011. Data regarding age, gender, tumor location, tumor size, tumor extension, radiation therapy, and local recurrences were reviewed and analyzed statistically. Results: All patients underwent intralesional resection. The average duration of follow-up was 86.4 months (range, 15 - 193 months). 8 (28.6%) patients developed local recurrence. The average recurrence time was 35.6 months (range, 5 - 79 months), and the local recurrence- free survival rates at 3 and 5 years were 89.1% and 75.5%, respectively. LRFS was found statistically longer in intracompartmental (T1) tumors as compared with extracompartmental (T2) tumors (P<0.05), but not for age, gender, tumor location, tumor size, or radiation therapy. CONCLUSION: Intralesional excision with preoperative embolization is a feasible choice for T1 tumors of the sacrum and mobile spine, but for T2 tumors, more aggressive treatment may be required. The choice of surgical treatment should be balanced between the complications and tumor recurrence.

Özet

AMAÇ: Preoperatif embolizasyonla kombine mobil omurga ve sakrum dev hücreli tümör cerrahi tedavisinden sonra yerel nükssüz sağkalım süresi (LRFS) ile ilişkili faktörleri incelemek. YÖNTEM ve GEREÇLER: 1995 ile 2011 yılları arasında preoperatif embolizasyonla kombine başlangıç cerrahi eksizyonu yapılan mobil omurga ve sakrum dev hücreli tümörü olan arka arkaya 28 hastayı retrospektif olarak değerlendirdik. Yaş, cinsiyet, tümör konumu, tümör büyüklüğü, tümör uzanması, radyasyon tedavisi ve yerel nükslerle ilişkili veriler değerlendirilip istatistiksel olarak analiz edildi. BULGULAR: Tüm hastalara intralezyonel rezeksiyon yapıldı. Ortalama takip süresi 86,4 aydı (aralık, 15 - 193 ay). 8 (%28,6) hastada yerel nüks gelişti. Ortalama nüks süresi 35,6 aydı (aralık 5 - 79 ay) ve yerel nükssüz sağkalım oranı 3 ve 5 yılda sırasıyla %89,1 ve %75,5 bulundu. LRFS intrakompartmantal (T1) tümörlerde ekstrakompartmantal (T2) tümörlere göre istatistiksel olarak daha uzundu (P<0,05) ama yaş, cinsiyet, tümör konumu, tümör büyüklüğü veya radyasyon tedavisinin bir farkı yoktu. SONUÇ: Preoperatif embolizasyonla intralezyonel eksizyon, mobil omurga ve sakrumun T1 tümörleri için iyi bir tercihtir ama daha agresif tedavinin gerekebileceği T2 tümörleri için iyi bir tercih değildir. Cerrahi tedavi tercihi komplikasyonlar ve tümör nüksü arasında dengelenmelidir.

🔖

Cite This Article

MING, Z., KANGWU, C., HUILIN, Y., GENLIN, W., JIAN, L., YIMING, J., CHUNSHEN, W., CHAO, C. (2013). Preoperatif Embolizasyonla Kombine Mobil Omurga ve Sakrum Dev Hücreli Tümörü Nüksü Risk Faktörleri Analizi. Turkish Neurosurgery, Cilt: 23 - Sayı: 5, 645–652. https://ajindex.com/articles/405504

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Arbeitsgemeinschaft Knochentumoren: Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am 90: 1060-1067, 2008 2. Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, Koehler G, Hardes J, Gosheger G: Giant cell tumor of bone: Treatment and outcome of 214 cases. J Cancer Res Clin Oncol 134: 969-978, 2008 3. Boriani S, Bandiera S, Casadei R, Boriani L, Donthineni R, Gasbarrini A, Pignotti E, Biagini R, Schwab JH: Giant cell tumor of the mobile spine: A review of 49 cases. Spine 37: E37-45, 2012 4. Cohen DM, Maccarty CS, Dahlin DC: Vertebral giant-cell tumor + variants. Cancer 17: 461-472, 1964 5. Campanacci M, Baldini N, Boriani S, Sudanese A: Giant-cell tumor of bone. J Bone Joint Surg Am 69: 106-114, 1987 6. Dahlin DC, Cupps RE, Johnson EW: Giant-cell tumor: A study of 195 cases. Cancer 25: 1061-1070, 1970 7. Enneking WF, Spanier SS, Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 153: 106-120, 1980 8 Enneking WF: A system of staging of musculoskeletal neoplasms. Clin Orthop Relat Res 204: 9-24, 1986 9. Errani C, Ruggieri P, Asenzio MAN, Toscano A, Colangeli S, Rimondi E, Rossi G, Longhi A, Mercuri M: Giant cell tumor of the extremity: A review of 349 cases from a single institution. Cancer Treat Rev 36: 1-7, 2010 10. Feigenberg SJ, Marcus RB, Zlotecki RA, Scarborough MT, Berrey BH, Enneking WF: Radiation therapy for giant cell tumors of bone. Clin Orthop Relat Res 411: 207-216, 2003 11. Goldenbe RR, Campbell CJ, Bonfigli M: Giant-cell tumor of bone: An analysis of 218 cases. J Bone Joint Surg Am 52: 619-664, 1970 12. Guzman R, Dubach-Schwizer S, Heini P, Lovblad KO, Kalbermatten D, Schroth G, Remonda L: Preoperative transarterial embolization of vertebral metastases. Eur Spine J 14: 263-268, 2005 13. Hart RA, Boriani S, Biagini R, Currier B, Weinstein JN: A system for surgical staging and management of spine tumors: a clinical outcome study of giant cell tumors of the spine. Spine 22: 1773-1782, 1997 14. Jeys LM, Suneja R, Chami G, Grimer RJ, Carter SR, Tillman RM: Impending fractures in giant cell tumours of the distal femur: Incidence and outcome. Int Orthop 30: 135-138, 2006 15. Kivioja AH, Blomqvist C, Hietaniemi K, Trovik C, Walloe A, Bauer HCF, Jorgensen PH, Bergh P, Folleras G: Cement is recommended in intralesional surgery of giant cell tumors: A Scandinavian Sarcoma Group study of 294 patients followed for a median